Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

E. Annels, Nicola; Mansfield, David; Arif, Mehreen; Ballesteros-Merino, Carmen; R. Simpson, Guy; Denyer, Mick; S. Sandhu, Sarbjinder; A. Melcher, Alan; J. Harrington, Kevin; Davies, Bronwyn; Au, Gough; Grose, Mark; Bagwan, Izhar; Fox, Bernard; Vile, Richard; Mostafid, Hugh; Shafren, Darren; S. Pandha, Hardev

doi:10.1158/1078-0432.ccr-18-4022

Public

Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Shared by NobleBlocks on Oct 1, 2019 • 12:00 AM UTC

Authors:

Nicola E. Annels

David Mansfield

Mehreen Arif

Abstract

Abstract Purpose: The CANON [CAVATAK in NON–muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1–targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. Patients and Methods: Fifteen patients enrolled in this “window of opportunity” phase I ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!